-0.0338  (-3.32%)
Volume (24h): 5.17M Day Range: 1.01 - 1.05
Market Cap: 104.31M 52W Range: 0.1033 - 3.40
Mar-26-20 08:20PM iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab BiosimilarGlobeNewswire
11:30AM iBio Announces Advancement of COVID-19 Vaccine ProgramGlobeNewswire
Mar-20-20 03:38PM Don’t Waste Time and Risk Capital on Coronavirus Play IBIO StockInvestorPlace
11:30AM iBio Joins the Alliance for BiosecurityGlobeNewswire
Mar-18-20 12:00PM iBio Announces Development of Proprietary COVID-19 Vaccine CandidatesGlobeNewswire
Mar-13-20 12:08PM iBio Stock Is Unlikely a Coronavirus Winner and Thus a Real GambleInvestorPlace
Mar-12-20 08:45PM iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEOGlobeNewswire
Mar-05-20 04:25PM Stocks give up much of Wednesday’s gain as coronavirus stalks marketsMarketWatch
03:23PM Stocks give up much of Wednesday’s gain as coronavirus stalks marketsMarketWatch
Mar-05-20 01:07PM iBio stock surges 19% premarket on hopes for plans to develop plant-based coronavirus vaccineMarketWatch
Mar-02-20 09:30PM iBio, Inc. Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock SplitGlobeNewswire
Feb-28-20 03:12PM iBio shares soar another 174% on hopes for China vaccine partnershipMarketWatch
Feb-17-20 01:52PM Here's Why iBio (NYSEMKT:IBIO) Must Play Its Cards Just RightSimply Wall St.
Feb-06-20 09:30PM iBio, Inc. Announces Postponement of Annual MeetingGlobeNewswire
Feb-04-20 01:54PM Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 4, 2020: GOOGL, DIS, EBAY, F, IBIOBenzinga
Feb-03-20 09:15PM iBio and CC-Pharming Initiate Joint Development of Coronavirus VaccineGlobeNewswire
Jan-16-20 01:00PM iBio, Inc. Announces NYSE American Acceptance of Plan of ComplianceGlobeNewswire
Jan-06-20 02:15PM iBio Initiates New Litigation Against FraunhoferGlobeNewswire
Dec-23-19 02:30PM EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facilityGlobeNewswire
01:30PM iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics ManufacturingGlobeNewswire
Dec-19-19 04:22PM Is iBio, Inc.'s (NYSEMKT:IBIO) CEO Being Overpaid?Simply Wall St.
Dec-16-19 09:15PM iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-PharmingGlobeNewswire
Dec-13-19 10:00PM iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance PlanGlobeNewswire
Dec-10-19 09:44PM iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein ProductionGlobeNewswire
Dec-03-19 05:31PM iBio Joins Manufacturing USA’s Tissue Biofabrication InitiativeGlobeNewswire
Dec-02-19 09:15PM iBio to Present at the First Annual BioTuesdays Pre-JPM Virtual ConferenceGlobeNewswire
Oct-25-19 12:30PM iBio, Inc. Prices $5,000,000 Public OfferingGlobeNewswire
Oct-22-19 08:30PM iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance PlanGlobeNewswire
Sep-19-19 05:58PM One Thing To Remember About The iBio, Inc. (NYSEMKT:IBIO) Share PriceSimply Wall St.
Sep-17-19 08:15PM iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next StageGlobeNewswire
Aug-26-19 09:30PM iBio and CC-Pharming Expand Business Collaboration in ChinaGlobeNewswire
Aug-21-19 04:15PM A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019Benzinga
Aug-19-19 08:35PM iBio Inks 3D Bioprinting AgreementGlobeNewswire
Jul-25-19 03:16PM Did Changing Sentiment Drive iBio's (NYSEMKT:IBIO) Share Price Down A Painful 89%?Simply Wall St.
Jun-19-19 12:00PM iBio Announces First Agreement for Fill-Finish ServicesGlobeNewswire
Jun-10-19 05:58PM How Should Investors React To iBio, Inc.'s (NYSEMKT:IBIO) CEO Pay?Simply Wall St.
Jun-03-19 12:00PM iBio Launches New Sterile Fill-Finish ServicesGlobeNewswire
Apr-24-19 06:03PM What Type Of Shareholder Owns iBio, Inc.'s (NYSEMKT:IBIO)?Simply Wall St.
Apr-01-19 12:30PM iBio Announces Appointment of Thomas F. Isett to Board of DirectorsGlobeNewswire
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)